Universe pharmaceuticals inc receives nasdaq delisting notice subject to hearing request

Ji'an, jiangxi, china, feb. 03, 2025 (globe newswire) -- universe pharmaceuticals inc (the “company”) (nasdaq: upc), a pharmaceutical producer and distributor in china, today announced that the company received a letter from the nasdaq stock market llc (“nasdaq”) on january 29, 2025, notifying the company that the nasdaq staff has determined to delist the company's ordinary shares from the nasdaq capital market (the “delisting determination”), because the bid price of the company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the nasdaq listing rule 5550(a)(2) (the “rule”). normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule. however, pursuant to the nasdaq listing rule 5810(c)(3)(a)(iv), the company is not eligible for any compliance period specified in nasdaq listing rule 5810(c)(3)(a) due to the fact that the company effected a reverse stock split on november 18, 2024, or within the prior one-year period.
NDAQ Ratings Summary
NDAQ Quant Ranking